-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2023-509261-20-00
4
2026-02-09
Ischemic stroke
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2025-520688-42-00
4
2026-01-27
Amyotrophic Lateral Sclerosis (ALS)
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2024-516471-33-00
4
2026-01-19
Alport Syndrome
-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2024-520384-14-00
4
2025-11-20
Centre-involved diabetic macular edema
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-518438-94-00
4
2025-10-24
Heart failure
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2023-509275-17-00
5
2025-10-06
Relapsing multiple sclerosis
-
2024-515682-34-00
5
2025-10-06
Chronic migraine
-
2024-515715-22-00
5
2025-10-06
Episodic migraine
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients